129 related articles for article (PubMed ID: 15156965)
1. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo RJ
Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
[TBL] [Abstract][Full Text] [Related]
2. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
Frampton JE; Easthope SE
Drugs; 2004; 64(21):2475-92. PubMed ID: 15482004
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib for advanced or metastatic non-small cell lung cancer.
Perras C
Issues Emerg Health Technol; 2004 Apr; (55):1-4. PubMed ID: 15085875
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib therapy for advanced non-small-cell lung cancer.
Liu CY; Seen S
Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
[TBL] [Abstract][Full Text] [Related]
15. [Gefitinib in the treatment of advanced non-small cell lung cancer].
Yang L; Liu XY; Fang J; An TT; Wu MN
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
[TBL] [Abstract][Full Text] [Related]
16. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
17. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib: current status in the treatment of non-small cell lung cancer.
Tanović A; Alfaro V
Drugs Today (Barc); 2004 Oct; 40(10):809-27. PubMed ID: 15605116
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
del Giglio A; Ito C
Sao Paulo Med J; 2004 May; 122(3):128-30. PubMed ID: 15448812
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]